Work

Repurposing Anthelmintics and Related Antiparasitic Drugs for Fibrosis: Evidence for Reduced Matrix Accumulation and the Question of Regression

Year: 2026
Type: preprint
Abstract: This critical narrative review examines the evidence for repurposing anthelmintics and related antiparasitic drugs in fibrosis. It asks whether these drugs reduce extracellular matrix production, limit tissue accumulation during ongoing injury, or promote regression of matrix already deposited before treatment. The review compares cell and tissue assays, early and delayed interventions in animal models, and studies of residual fibrosis after parasite clearance. For each comparison, it considers when treatment began, whether matrix burden was measured at that point, what the comparator can establish, and how the outcome was measured. It also distinguishes effects observed after the last dose from effects that persist after drug clearance has been verified. Selected preclinical studies reported lower final matrix burden after delayed treatment in lung, cardiac and renal models. Without a comparable pretreatment matrix measurement, these results leave open whether matrix burden declined during treatment. Studies of infection-associated fibrosis illustrate a further challenge in attributing matrix changes to the drug when parasite clearance also reduces the stimulus for new deposition. Table 1 summarises selected delayed-treatment comparisons. Supplementary Table S1 documents the studies discussed in the current synthesis and identifies provisional extractions based on abstracts. Full-text assessment of the broader search remains in progress.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7233882927
Cites:
Cited by:
Related to: 10